Insights

Clinical-stage focus AsclepiX Therapeutics is a clinical-stage biopharmaceutical company with a lead candidate AXT107 targeting retinal vascular diseases, presenting an opportunity to offer specialized CRO, clinical trial support, and regulatory consulting services aligned with ophthalmology and vascular biology.

Funding momentum Recent Series A-3 financing of 10 million signals ongoing investor support and potential for partnership discussions, making it a favorable time to propose collaboration on co-development, strategic licensing, or research services tied to retinal disease programs.

Small team agility With a lean employee base (2-10), the company may seek external expertise in areas such as trial optimization, regulatory affairs, pharmacovigilance, and manufacturing scale-up, creating demand for contracted services and advisory partnerships.

Computational biology edge Leveraging Johns Hopkins–level computational biology to identify peptide regulators suggests opportunities to offer data analytics, bioinformatics collaboration, peptide design optimization, and companion diagnostic development to accelerate program milestones.

Retinal disease focus Strategic sales conversations can target ophthalmology clinics, eye research institutions, and retinal disease consortia for collaboration on preclinical models, translational research, or access to specialized biomarkers and model systems relevant to VEGFR2 and Tie2 pathways.

Similar companies to AsclepiX Therapeutics

AsclepiX Therapeutics Tech Stack

AsclepiX Therapeutics uses 8 technology products and services including RSS, WordPress, Shopify, and more. Explore AsclepiX Therapeutics's tech stack below.

  • RSS
    Content Management System
  • Content Management System
  • E-commerce
  • Google Fonts API
    Font Scripts
  • Infrastructure As A Service
  • Elementor
    Page Builders
  • jQuery Waypoints
    Web Tools And Plugins

Media & News

AsclepiX Therapeutics's Email Address Formats

AsclepiX Therapeutics uses at least 2 email formats:
AsclepiX Therapeutics Email FormatsExamplePercentage
FLast@asclepix.comJDoe@asclepix.com
90%
LastFirst@asclepix.comDoeJohn@asclepix.com
10%

Frequently Asked Questions

What is AsclepiX Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
AsclepiX Therapeutics's official website is asclepix.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does AsclepiX Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2026, AsclepiX Therapeutics's annual revenue is estimated to be $1M - $10M.

What is AsclepiX Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
AsclepiX Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does AsclepiX Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2026, AsclepiX Therapeutics has approximately 4 employees across 2 continents, including North America and Asia. Key team members include Adobe Acrobat Document [: D. B. Explore AsclepiX Therapeutics's employee directory with LeadIQ.

What industry does AsclepiX Therapeutics belong to?

Minus sign iconPlus sign icon
AsclepiX Therapeutics operates in the Biotechnology Research industry.

What technology does AsclepiX Therapeutics use?

Minus sign iconPlus sign icon
AsclepiX Therapeutics's tech stack includes RSS, WordPress, Shopify, Microsoft 365, Google Fonts API, Google Cloud, Elementor and jQuery Waypoints.

What is AsclepiX Therapeutics's email format?

Minus sign iconPlus sign icon
AsclepiX Therapeutics's email format typically follows the pattern of FLast@asclepix.com. Find more AsclepiX Therapeutics email formats with LeadIQ.

How much funding has AsclepiX Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2026, AsclepiX Therapeutics has raised $50M in funding. The last funding round occurred on Jul 26, 2023 for $10M.
AsclepiX Therapeutics logo

AsclepiX Therapeutics

Biotechnology ResearchMaryland, United States2-10 Employees

AsclepiX Therapeutics is a clinical-stage biotechnology company focused on developing peptide-based therapies for retinal diseases. It leverages computational biology from Johns Hopkins to identify peptide regulators of vascular and cellular homeostasis, guiding the development of candidates for retinal conditions. The lead candidate, AXT107, inhibits pro-angiogenic VEGFR2 signaling and activates the vessel-stabilizing Tie2 receptor.

Based in Baltimore, Maryland, the company operates within the biotechnology sector's ophthalmology and vascular biology niche, aiming to address vision-threatening retinal vascular diseases. Its work targets patients whose retinal conditions involve abnormal blood vessel growth and vascular instability, seeking therapies that modulate these pathways.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
2-10

Section iconFunding & Financials

  • $50M

    AsclepiX Therapeutics has raised a total of $50M of funding over 3 rounds. Their latest funding round was raised on Jul 26, 2023 in the amount of $10M as a Series A.

  • $1M - $10M

    AsclepiX Therapeutics's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.